AUPH

Aurinia Pharmaceuticals Inc.

Price

$16.32

return (12m)

36.11%

p/e

6.75

p/bv

3.45

DIVIDEND YIELD

0.00%

AUPH price

Aurinia Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment AUPH

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

11.63%

3 months

6.46%

1 year

36.11%

2 years

136.52%

5 years

0.25%

10 years

736.92%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals AUPH

Valuation

P/E

6.75

Sector -4.19

Industry -4.19

P/BV

3.45

Sector 2.11

Industry 2.11

P/Revenue (PSR)

6.81

Sector 2.08

Industry 2.08

EV/EBITDA

30.76

Sector -546.32

Industry -546.32

EV/EBIT

33.75

Sector -37.38

Industry -37.38

P/EBITDA

11.54

Sector -50.76

Industry -50.76

P/EBIT

12.90

Sector -39.31

Industry -39.31

P/Total Assets

2.68

Sector 1.25

Industry 1.25

P/Net Current Assets

5.83

Sector -5.50

Industry -5.50

P/Working Capital

4.81

Sector -1.26

Industry -1.26

EPS

2.42

Sector -1.92

Industry -1.92

BVPS

4.73

Sector 1.91

Industry 1.91

Efficiency

Gross Margin

90.36%

Sector 39.00%

Industry 39.00%

EBITDA Margin

65.57%

Sector -13,872.56%

Industry -13,872.56%

EBIT Margin

59.76%

Sector -4,253,834.43%

Industry -4,253,834.43%

Operating Margin

48.39%

Sector -36.72%

Industry -36.72%

Net Profit Margins

100.00%

Sector -37.51%

Industry -37.51%

Asset Turnover

0.11

Sector 0.03

Industry 0.03

Profitability

ROE

51.08%

Sector -60.65%

Industry -60.65%

ROA

39.65%

Sector -63.20%

Industry -63.20%

ROIC

49.94%

Sector -498.30%

Industry -498.30%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

5.42

Sector 2.89

Industry 2.89

Net Debt / EBITDA

-8.12

Sector -39,048,222.71

Industry -39,048,222.71

Net Debt / EBIT

-8.91

Sector -10.24

Industry -10.24

Net Debt / Equity

-0.72

Sector -0.60

Industry -0.60

Gross Debt / Equity

0.00

Sector -0.83

Industry -0.83

Equity/Assets

0.78

Sector 0.43

Industry 0.43

Liabilities/Assets

0.22

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

46.86%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

FAIR VALUE OF Aurinia Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$16.32

Fair Value

$16.05

Upside Return potential.

-1.66%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals AUPH

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
AUPH Aurinia Pharmaceuticals Inc.	$16.32	34.76%	0.00%	6.75	3.45	51.08%	100.00%
JNJ Johnson & Johnson	$266.50	55.29%	1.98%	30.34	7.51	24.76%	21.48%
PFE Pfizer Inc.	$27.87	21.03%	6.28%	35.72	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$256.91	27.42%	2.66%	72.02	-76.66	-106.44%	9.81%
NVO Novo Nordisk A/S	$45.62	-14.65%	4.06%	11.16	5.92	53.11%	35.32%
MRK Merck & Co. Inc.	$147.77	82.63%	2.29%	114.53	8.64	7.55%	4.76%
AZN AstraZeneca PLC	$161.98	3.71%	1.99%	23.89	4.95	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$66.29	45.78%	3.79%	14.60	6.06	41.55%	18.85%
ZTS Zoetis Inc.	$76.84	-49.43%	2.68%	12.14	10.20	84.02%	27.77%
AMGN Amgen Inc.	$432.42	55.55%	2.28%	26.55	19.86	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$792.43	37.47%	0.58%	18.86	2.57	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$105.00	43.48%	0.00%	29.70	85.59	288.14%	24.86%
MCK McKesson Corporation	$897.16	31.93%	0.37%	20.12	-27.60	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$542.40	39.41%	0.00%	31.27	6.80	21.76%	35.00%
CAH Cardinal Health Inc.	$235.19	59.60%	0.87%	35.62	-20.64	-57.93%	0.62%
HRMY Harmony Biosciences Holdings Inc.	$39.29	3.26%	0.00%	12.57	2.28	18.14%	18.89%
ARGX argenx SE	$1,033.89	46.04%	0.00%	3.11	3.48	112.18%	44.41%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

AUPH Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (4 people)

United States

15 years

Founded: 2011

2009

Time since IPO - 17 years

62

Employees

Aurinia Pharmaceuticals Inc. (United States) is listed on the Nasdaq and has a market capitalization of $2.12 billion, with shareholders equity totaling $614.86 million.

The company employs approximately 62 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Aurinia Pharmaceuticals Inc. reported $311.50 million in revenue, generating net income of $314.10 million.

Key financial metrics include a P/E ratio of 6.75, a price-to-book (P/B) ratio of 3.45, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker AUPH.

Market cap

$2.12 billion

Net worth

$614.86 million

$614,860,000.00

Assets

$792.26 million

$792,260,000.00

Total Shares Outstanding

130.00 million

130,000,000

Average Daily Trading Volume

$1.51 million

$1,511,838.00

Sector

Health Care

Industry

Biotechnology

AUPH

AUPH revenue and profits

Financial Results AUPH

DRAG THE FRAME TO SEE MORE DATA

AUPH cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$897.16 31,19% (12M)

P/E

20.12

0.37%

ROE

-137.16%

P/BV

-27.60

CAH - Cardinal Health

$235.19 59,74% (12M)

P/E

35.62

0.87%

ROE

-57.93%

P/BV

-20.64

JNJ - Johnson & Johnson

$266.50 54,20% (12M)

P/E

30.34

1.98%

ROE

24.76%

P/BV

7.51

ABBV - AbbVie

$256.91 26,00% (12M)

P/E

72.02

2.66%

ROE

-106.44%

P/BV

-76.66

MRK - Merck & Co.

$147.77 81,49% (12M)

P/E

114.53

2.29%

ROE

7.55%

P/BV

8.64

AZN - AstraZeneca

$161.98 2,77% (12M)

P/E

23.89

1.99%

ROE

20.74%

P/BV

4.95

PFE - Pfizer

$27.87 20,44% (12M)

P/E

35.72

6.28%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$897.16 31,19% (12 M)

P/L

20.12

0.37%

ROE

-137.16%

P/VP

-27.60

CAH - Cardinal Health

$235.19 59,74% (12 M)

P/L

35.62

0.87%

ROE

-57.93%

P/VP

-20.64

JNJ - Johnson & Johnson

$266.50 54,20% (12 M)

P/L

30.34

1.98%

ROE

24.76%

P/VP

7.51

ABBV - AbbVie

$256.91 26,00% (12 M)

P/L

72.02

2.66%

ROE

-106.44%

P/VP

-76.66

MRK - Merck & Co.

$147.77 81,49% (12 M)

P/L

114.53

2.29%

ROE

7.55%

P/VP

8.64

AZN - AstraZeneca

$161.98 2,77% (12 M)

P/L

23.89

1.99%

ROE

20.74%

P/VP

4.95

PFE - Pfizer

$27.87 20,44% (12 M)

P/L

35.72

6.28%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Aurinia Pharmaceuticals (AUPH) today?

A cotação de Aurinia Pharmaceuticals (AUPH) hoje está em US$ 16.32, com uma variação de 36.11% em relação ao último ano. A cotação de Aurinia Pharmaceuticals (AUPH) iniciou o ano negociando na casa dos US$ 15.95 e hoje está em US$ 16.32. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Aurinia Pharmaceuticals (AUPH) e dados de ações do Ibovespa e mercados internacionais.

Quando Aurinia Pharmaceuticals (AUPH) paga dividendos?

Aurinia Pharmaceuticals (AUPH) não distribuiu dividendos no último ano.

Is Aurinia Pharmaceuticals (AUPH) a good investment?

Atualmente, Aurinia Pharmaceuticals (AUPH) está cotada a US$ 16.32, com um P/L de 6.75, representando um desvio de 4,364% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 36.11 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 36.11%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Aurinia Pharmaceuticals (AUPH) stock?

Investir em ações de Aurinia Pharmaceuticals (AUPH) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Aurinia Pharmaceuticals (AUPH) yield today?

A rentabilidade de Aurinia Pharmaceuticals (AUPH) foi de 11.63% no último mês, 36.11% no último ano e 0.25% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Aurinia Pharmaceuticals (AUPH) hoje, o investimento total seria de US$ 1,632.00, com base na cotação atual de US$ 16.32.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 2,221.32
Em 5 anos: US$ 1,636.08
Em 10 anos: US$ 13,658.53

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

AUPH

Aurinia Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment AUPH

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING AUPH WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc.

United States

15 years

2009

62

PROFIT X PRICE AUPH

Financial Results AUPH

AUPH cash flow

Asset, Revenue and Profit Growth - AUPH

AUPH balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions